Background: Few large studies have assessed spironolactone treatment of adult female acne. Objectives: To explore the role of spironolactone in the treatment of adult female acne. Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions: Spironolactone is a safe and effective treatment of acne for women.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of the European Academy of Dermatology and Venereology|
|State||Published - Sep 1 2020|
ASJC Scopus subject areas
- Infectious Diseases